Copy Link Print Information

Pumitamig

(Synonyms: PM-8002; BNT-327)
Customer Review

Based on 1 Customer Validation

Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.

For research use only. We do not sell to patients.

  • Purity: 99.6%
  • Molecular Weight:172.48 kDa
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Pumitamig
  • Experimental Validation Results for Pumitamig
  • Experimental Validation Results for Pumitamig
  • Experimental Validation Results for Pumitamig
  • Experimental Validation Results for Pumitamig
  • Pumitamig Chemical Structure
    Pumitamig Chemical Structure
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Pumitamig:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

All VEGFR Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    IgG1-kappa-VH

  • 1/16

    Immobilized hu-PD-L1-ECD-His can bind PM-8002. The EC50 for this effect is 116.7 ng/mL.

  • 1/16

    Immobilized rhVEGF can bind PM-8002. The EC50 for this effect is 19.39 ng/mL.

  • 1/16

    Flow Cytometry analysis of Hela cells labelling PD-1 (red) with Pumitamig (anti-PD-1) (HY-P991097). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99991, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • 1/16

    Flow Cytometry analysis of K562 cells labelling VEGF (red) with Pumitamig (HY-P991097). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • Pumitamig Chemical Structure
    1/16
  • Pumitamig
  • Immobilized hu-PD-L1-ECD-His can bind PM-8002. The EC50 for this effect is 116.7 ng/mL.
  • Immobilized rhVEGF can bind PM-8002. The EC50 for this effect is 19.39 ng/mL.
  • Flow Cytometry analysis of Hela cells labelling PD-1 (red) with Pumitamig (anti-PD-1) (HY-P991097). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99991, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Flow Cytometry analysis of K562 cells labelling VEGF (red) with Pumitamig (HY-P991097). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • IgG1-kappa-VH